Brickell Competitors

Delisted . USA . 
Stock . Brickell Biotech
BBIDelisted Stock  USD 1.79  0.34  23.45%   
Brickell Biotech competes with Griffon, Cardinal Health, Tandem Diabetes, Aquestive Therapeutics, and Microbot Medical; as well as few others. The company runs under Biotechnology sector within Health Care industry. Analyzing Brickell Biotech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Brickell Biotech to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Brickell Biotech competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
1.791.791.79
Details
Intrinsic
Valuation
LowRealHigh
1.461.461.97
Details
Naive
Forecast
LowNextHigh
1.911.911.91
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.431.631.84
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Brickell Biotech. Your research has to be compared to or analyzed against Brickell Biotech's peers to derive any actionable benefits. When done correctly, Brickell Biotech's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Brickell Biotech.

Brickell Biotech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Brickell Biotech and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Brickell and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Brickell Biotech does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CAH
+ 0.75
GFF
MBOT
+ 0.41
CAH
MBOT
+ 0.39
AQST
MBOT
+ 0.19
GFF
GTCDF
+ 0.0
GFF
GTCDF
+ 0.0
CAH
  
High negative correlations   
TNDM
- 0.67
CAH
MBOT
- 0.57
TNDM
TNDM
- 0.45
GFF
AQST
- 0.34
TNDM
AQST
- 0.13
CAH
AQST
- 0.12
GFF

Risk-Adjusted Indicators

There is a big difference between Brickell Stock performing well and Brickell Biotech Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Brickell Biotech's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Brickell Biotech Competitive Analysis

The better you understand Brickell Biotech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Brickell Biotech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Brickell Biotech's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BBI GFF CAH TNDM AQST GTCDF MBOT
 23.45 
 1.79 
Brickell
 1.95 
 82.66 
Griffon
 0.19 
 122.47 
Cardinal
 6.14 
 32.51 
Tandem
 5.50 
 4.81 
Aquestive
 0.00 
 0.05 
Getty
 3.09 
 1.00 
Microbot
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Moderately volatile
Very steady
Unstable
Market Performance
(90 Days Performance)
Very Weak
Good
Modest
Very Weak
OK
Very Weak
Modest
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Very Low
Very Low
Below Average
Below Average
Quite High
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Buy
Strong Buy
Strong Buy
Not Available
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Hold
Strong Hold
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Current Ratio
4.36 X
2.26 X
1.04 X
4.80 X
1.47 X
0.03 X
5.60 X
Net Asset
29.72 M
2.37 B
45.12 B
952.66 M
57.42 M
6.37 M
8.33 M
Profit Margin
N/A
0.08 %
0.01 %
(0.15) %
(0.60) %
N/A
N/A
EBITDA
(39.38 M)
461.44 M
1.98 B
(194.66 M)
1.18 M
(216.52 K)
(10.63 M)
Operating Margin
(6.58) %
0.20 %
0.01 %
(0.11) %
(0.61) %
N/A
N/A
Current Valuation
(8.35 M)
5.62 B
31.88 B
2.01 B
423.07 M
4.71 M
12.25 M
Price To Book
0.41 X
17.93 X
16.07 X
8.46 X
N/A
1.09 X
4.33 X
Retained Earnings
(145.37 M)
461.44 M
(286 M)
(951.8 M)
(319.08 M)
N/A
(79.5 M)
Current Asset
52.66 M
382.34 M
21.96 B
106.98 M
38.38 M
N/A
15.21 M
Five Year Return
N/A
1.48 %
3.61 %
N/A
N/A
N/A
N/A
Beta
0.0796
1.27
0.62
1.37
2.82
-0.16
1.63
Number Of Employees
16
N/A
47.92 K
2.4 K
135
13
21
Shares Outstanding
2.87 M
47.82 M
242.01 M
65.68 M
91.18 M
121.89 M
16.93 M
Cash Flow From Operations
(36.15 M)
380.04 M
3.76 B
(31.81 M)
(6.38 M)
(91.36 K)
(8.53 M)
Annual Yield
N/A
0.01 %
0.02 %
N/A
N/A
N/A
N/A
Total Debt
69 K
1.71 B
5.09 B
415.67 M
33.32 M
1.21 M
231 K
Return On Equity
-1.57
0.78
N/A
-0.46
N/A
-0.087
-1.34
Z Score
N/A
N/A
N/A
N/A
N/A
1.2
N/A
Return On Asset
-0.8
0.12
0.0318
-0.0969
-0.16
-0.0175
-0.65
Number Of Shares Shorted
189.59 K
2.32 M
5.98 M
7.38 M
9.97 M
N/A
586.82 K
Book Value Per Share
5.81 X
4.83 X
(13.54) X
3.62 X
(0.50) X
0.03 X
0.38 X
Current Liabilities
5.61 M
189.15 M
19.7 B
26.52 M
17.95 M
N/A
9.83 M
Total Asset
29.72 M
2.37 B
45.12 B
952.66 M
57.42 M
6.37 M
8.33 M
Debt To Equity
0 %
1.97 %
5.63 %
1.00 %
468.20 %
0.66 %
0.07 %
Short Ratio
0.62 X
4.83 X
2.67 X
4.72 X
6.12 X
N/A
2.65 X
Target Price
17.83
101.0
125.48
51.25
10.06
N/A
7.0
Last Dividend Paid
N/A
0.6
2.01
N/A
N/A
N/A
N/A
Shares Owned By Institutions
13.07 %
78.02 %
89.55 %
99.24 %
55.35 %
N/A
7.46 %
Market Capitalization
6.75 M
4.03 B
29.68 B
2.05 B
470.48 M
3.17 M
16.5 M
Price To Earning
(35.16) X
19.62 X
16.00 X
494.25 X
(1.90) X
(7.10) X
(3.42) X
Price To Earnings To Growth
N/A
2.36 X
1.03 X
N/A
N/A
N/A
N/A
Price To Sales
1.45 X
1.54 X
0.13 X
2.40 X
7.99 X
N/A
N/A
Net Income
(39.47 M)
209.9 M
852 M
(222.61 M)
(7.87 M)
(329.17 K)
(10.74 M)
Earnings Per Share
(0.42) X
4.23 X
5.20 X
(1.94) X
(0.45) X
(0) X
(0.79) X
Shares Owned By Insiders
1.20 %
18.48 %
0.25 %
0.76 %
5.00 %
51.51 %
1.42 %
Revenue
404 K
2.62 B
226.83 B
747.72 M
50.58 M
N/A
N/A
Working Capital
24.79 M
580.49 M
(756 M)
552.73 M
22.66 M
N/A
4.13 M
Cash And Equivalents
17.29 M
120.18 M
4.04 B
608.73 M
17.7 M
38.59 K
9.29 M
Cash Per Share
6.52 X
2.81 X
13.32 X
9.47 X
0.33 X
N/A
1.31 X
Gross Profit
(27.83 M)
1.03 B
6.54 B
412.99 M
28.29 M
N/A
N/A
Day Typical Price
1.73
82.96
122.43
32.68
4.96
0.0488
1.01
Accumulation Distribution
0.28
11004.22
29707.58
83602.91
241938.0
N/A
8335.91
Market Facilitation Index
0.56
0.0
0.0
0.0
N/A
N/A
N/A
Daily Balance Of Power
0.6071
(0.62)
0.1503
1.062147
(0.54)
0.0
0.6
Period Momentum Indicator
0.34
(1.64)
0.23
1.88
(0.28)
N/A
0.03
Rate Of Daily Change
1.23
0.98
1.0
1.06
0.94
1.0
1.03
Day Median Price
1.7
83.11
122.41
32.77
5.03
0.0488
1.02
Price Action Indicator
0.26
(1.27)
0.18
0.68
(0.36)
N/A
N/A
Coefficient Of Variation
17032.34
674.48
918.48
(605.36)
1638.15
N/A
3995.6
Mean Deviation
4.71
1.73
1.03
2.4
3.36
N/A
2.09
Jensen Alpha
(0.05)
0.2114
0.0747
(0.68)
0.025
N/A
0.0229
Total Risk Alpha
(1.03)
(0.06)
(0.1)
(1.04)
(0.46)
N/A
(0.43)
Sortino Ratio
(0.02)
0.1441
0.0187
N/A
0.0293
N/A
(0.02)
Downside Variance
29.51
4.28
1.94
N/A
16.58
N/A
8.8
Standard Deviation
6.32
2.94
1.5
3.1
4.21
N/A
2.99
Kurtosis
1.84
20.19
5.97
0.4429
(0.08)
N/A
2.28
Potential Upside
7.3
3.14
2.12
4.24
6.51
N/A
5.38
Treynor Ratio
0.0455
0.2535
0.2483
(0.43)
0.142
N/A
0.1975
Maximum Drawdown
19.28
22.84
10.66
12.63
20.28
N/A
15.87
Variance
39.93
8.64
2.26
9.63
17.68
N/A
8.93
Market Risk Adjusted Performance
0.0555
0.2635
0.2583
(0.42)
0.152
N/A
0.2075
Risk Adjusted Performance
0.0133
0.1207
0.0881
(0.12)
0.0548
N/A
0.0266
Skewness
0.8275
3.29
1.07
0.0402
0.1661
N/A
0.9481
Semi Deviation
5.1
1.72
1.15
N/A
3.79
N/A
2.27
Information Ratio
(0.02)
0.1014
0.0174
(0.21)
0.0283
N/A
(0.02)
Value At Risk
(8.12)
(3.11)
(1.97)
(4.60)
(7.14)
N/A
(4.60)
Expected Short fall
(6.25)
(1.96)
(1.13)
N/A
(3.61)
N/A
(3.08)
Downside Deviation
5.43
2.07
1.39
N/A
4.07
N/A
2.97
Semi Variance
26.0
2.97
1.33
N/A
14.37
N/A
5.16

Brickell Biotech Competition Performance Charts

Five steps to successful analysis of Brickell Biotech Competition

Brickell Biotech's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Brickell Biotech in relation to its competition. Brickell Biotech's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Brickell Biotech in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Brickell Biotech's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Brickell Biotech, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Brickell Biotech position

In addition to having Brickell Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Corporate ETFs Thematic Idea Now

Corporate ETFs
Corporate ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Corporate ETFs theme has 222 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Other Consideration for investing in Brickell Stock

If you are still planning to invest in Brickell Biotech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Brickell Biotech's history and understand the potential risks before investing.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY